Alere
→
Abbott Laboratories
Acquisition · Cash + Stock · announced Feb 1, 2016
Announced
Feb 1, 2016
Closed
Oct 3, 2017
Economics
Cash + Stock()
Pre-deal · pre-deal mark: 2016, year precision · rounding grid ±$100M · Abbott 8-K filing, SEC EDGAR — Alere acquisition (NYSE:ALR market cap)
$51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Target
Alere
Diagnostics · Diagnostic / genomic
HQ Waltham, MA · Founded 2001
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
Acquirer
Abbott Laboratories
Healthcare
HQ Abbott Park, IL
Global healthcare company — diagnostics, medical devices, nutrition, pharmaceuticals; point-of-care testing leader via Alere acquisition
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Global leader in point-of-care diagnostics — $5.5B POC market includes rapid pregnancy, fertility, and women's health testing; expands Abbott's diagnostics presence in 100+ countries
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR — Abbott/Alere amended merger (Apr 14, 2017)
Tertiary (trade / analyst)
Abbott Mediaroom — closing (Sep 29, 2017)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/1800/000110465916092968/a16-3252_18k.htm
Open source
Limitations
- $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
- Pre-deal valuation sourced from: Abbott 8-K filing, SEC EDGAR — Alere acquisition (NYSE:ALR market cap). Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
Insufficient disclosed data
No verified Diagnostics deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| EUROIMMUN | PerkinElmer (Revvity) | Jun 16, 2017 | ||
| Counsyl | Myriad Genetics | May 28, 2018 | ||
| Sequenom | LabCorp | Jul 27, 2016 | ||
| nVision Medical | Boston Scientific | Apr 16, 2018 |
Other verified deals by Abbott Laboratories
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Abbott Laboratories are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Alere (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.